Product: CGS 21680 (Hydrochloride)
COMT Antibody Summary
| Immunogen |
Peptide with sequence GDTKEQRILNHVLQC corresponding to N-Terminus according to NP_000745.1, NP_001128633.1, NP_001128634.1, NP_009294.1.
|
| Specificity |
This antibody is expected to recognise both reported isoforms. Variants (NP_000745.1; NP_001128633.1; NP_001128634.1) encode the same isoform.
|
| Clonality |
Polyclonal
|
| Host |
Goat
|
| Gene |
COMT
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
||
| Application Notes |
WB: Approx. 26 kDa band plus 29 kDa band bands observed in human testis lysates (calculated MW of 30.0 kDa band according to NP_000745.1 and of 24.5 kDa band according to NP_009294.1).
|
||
| Positive Control |
|
||
| Publications |
|
Reactivity Notes
Predicted cross-reactivity based on sequence identity: Mouse, Rat, Canine.
Packaging, Storage & Formulations
| Storage |
Store at -20C. Avoid freeze-thaw cycles.
|
| Buffer |
0.5 mg/ml Tris (pH 7.3) and 0.5% BSA
|
| Preservative |
0.02% Sodium Azide
|
| Concentration |
0.5 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for COMT Antibody
- catechol O-methyltransferase
- catechol-O-methyltransferase
- COMT
- EC 2.1.1.6
Background
Catechol-O-methyltransferase catalyzes the transfer of a methyl group from S-adenosylmethionine to catecholamines, including the neurotransmitters dopamine, epinephrine, and norepinephrine. This O-methylation results in one of the major degradative pathways of the catecholamine transmitters. In addition to its role in the metabolism of endogenous substances, COMT is important in the metabolism of catechol drugs used in the treatment of hypertension, asthma, and Parkinson disease. COMT is found in two forms in tissues, a soluble form (S-COMT) and a membrane-bound form (MB-COMT). The differences between S-COMT and MB-COMT reside within the N-termini. The transcript variants are formed through the use of alternative translation initiation sites and promoters.